11/15
06:01 pm
tara
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology [Yahoo! Finance]
Medium
Report
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology [Yahoo! Finance]
11/15
05:52 pm
tara
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
Medium
Report
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
11/14
08:15 am
tara
Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Medium
Report
Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
11/12
08:00 am
tara
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
Low
Report
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
11/6
08:00 am
tara
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
High
Report
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
10/21
08:00 am
tara
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
Medium
Report
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
9/9
08:09 am
tara
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations [Yahoo! Finance]
Low
Report
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations [Yahoo! Finance]
9/9
08:05 am
tara
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
Medium
Report
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
9/9
08:00 am
tara
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
High
Report
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
9/3
08:00 am
tara
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Low
Report
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference